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Oral Presentations S159patient consult can proceed to HCT for MDS with a significant
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Objective:Hematopoietic Stem Cell Transplantation (HSCT) still
remains the only cure available for Major Thalassemia. Below there
are the results of 19 years using HSCT as treatment in our centre.
Patients and Methods: 425 Major Thalassemia Patients, (242 male
and 183 female) with a median age of 7 (Range: 2-28 years), have re-
ceived HSCT from July 1991 through October, 2009. From 425 pa-
tients, 113 patients were in class I, 146 in class II, 142 in class III and
24 inThalassemia Intermediate. They received allogeneic transplanta-
tion from 407 HLA full matched siblings, nine HLA mismatched sib-
lings or other relatives, nine HLA full matched other relatives. The
sources of HSCT were 158 bone marrow, 194 peripheral blood, 9
cord blood and one bone marrow combined with peripheral blood.
Since three years ago 58 patients with class III thalassemia were ran-
domized for double blind study with two groups; one with co-trans-
plantation (mesenchymalcells) andanotherwithoutmesenchymalcells.
Results:Themedian time toAbsoluteNeutrophilCount$0.5 109/
L and platelet count $20 109/L were +15 and +22, respectively.
Acute GvHD occurred in 281 (66%) and chronic GvHD in 91
(21.4%) patients. 356 (83.8%) patients are still living and 69 (16.2%)
are deceased. The most common cause of death was GvHD. 5-year
overall survival (OS) and disease-free survival (DFS) were 79.8% and
70.2%, respectively. The 5-year OS of patients with peripheral blood
and bone marrow stem cell were 75.5% and 84.2%, respectively
(p5 .141). The 5-year DFS of peripheral blood and bone marrow
recipients were 69.3% and 73.1%, respectively (p5 .773). Up to now
the results ofHSCT for both groups in double blind randomized study
is same and we have to wait for future analysis.
Conclusion: HSCT, based on our experience and other docu-
mented studies, is an acceptable treatment for Major Thalassemia
with better results in younger patients.
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IL-15 ENHANCES IN-VITRO EXPANSION AND FUNCTIONAL ACTIVITY OF
ANTIGEN-SPECIFIC EFFECTOR MEMORY T CELLS (TEM) WHILE CO-
EXPRESSION OF IL-15 AND IL-15 R ON ANTIGEN PRESENTING CELLS
ALSO PROMOTES ENRICHMENT AND PREFERENTIAL EXPANSION OF
CENTRAL MEMORY T-CELLS (TCM)
Hasan, A.N.1, Selvakumar, A.1,2, Liu, X.-R.2, Sadelain, M.W.3,
Riviere, I.3, Dupont, B.2, O’Reilly, R.J.1,2 1Memorial Sloan-Kettering
Cancer Center, New York, NY; 2Sloan-Kettering Institute, New York,
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Adoptive immunotherapy with in-vitro expanded antigen-specific
T cells (TC) is often hampered by extended culture times and limited
persistence of infused cells in-vivo. IL-2 predominantly supports the
generation of short-lived effector memory (TEM) and effector (TE)
CD8+ TCwithout expanding the CD62L+ andCCR7+ central mem-
ory TC (TCM), which may persist longer in- vivo. We examined if
IL-15 could foster the growth of CMVpp65-specific TEM and
TCM CD8
+ TC.
TC from 6 HLA-A0201+ seropositive donors were sensitized in-
vitro using HLA-A0201+, CMVpp65+ artificial antigen presenting
cells (Hasan et al. JI, 2009) (A2-AAPC). To assess if trans-presenta-
tion of IL-15 on AAPCs leads to enhanced IL-15 activity, we sequen-
tially transduced A2-AAPCs with the IL-15 and IL-15 Ra cDNA
(A2-AAPCIL-15/IL-15Ra). TC were cultured using A2-AAPC with (i)
IL-2 (20U/ml) (ii) IL-15 (10ng/ml) (iii) IL-2 plus IL-15 or (iv)
A2-AAPCIL-15Ra + IL-2 (20U/ml) (v) A2-AAPCIL-15Ra + IL-15
(10ng/ml) or (vi) A2-AAPCIL-15/IL-15Ra
Starting from a precursor frequency of 0.5-2 x 104/5 million TC,
cultures supplemented with IL-15 demonstrated upto 2000 foldexpansion of CMVpp65 tetramer (+)TC and generated 25-70 x106
A2-NLV tetramer (+) CD8+ TC, compared to a 300-600 fold expan-
sion and 6-12 x106 tetramer (+) CD8+ TCwith IL-2 after 21-28 days.
Sensitization with A2-AAPCIL-15/IL-15Ra exhibited rapid and signif-
icant enrichment of CMVpp65 A2-NLV tetramer (+) CD8+ TC
between day 14-28. There were no TCM detected by 21 days among
tetramer (+) TC in cultures (i) to (v). However, TC sensitized with
A2-AAPCIL-15/IL-15Ra contained 12-15% (7106) tetramer (+)
CD8+ TCM which further increased through day 35. In functional
assays, sensitization with A2-AAPCIL-15/IL-15Ra generated 35-53%
CD8+ CMVpp65 epitope-specific IFNg+ TC compared to 11-26%
in cultures with exogenous IL-15 and 2-10% in cultures with IL-2.
Cytotoxic activity was also higher for TC sensitized with A2-AAP-
CIL-15/IL-15Ra (80-90%) compared to cultures with IL-2 (60%).
These data demonstrate that any condition using IL-15 generates
higher yields of antigen-specific TC. However, TC cultures supple-
mented with IL-15 +/- IL-2 only supported sustained expansion of
TEM and TE. In contrast, TC sensitized with A2-AAPC
IL-15/IL-15Ra
also supported sustained expansion of TCM with augmented
functional activity. Therefore AAPCIL-15/IL-15Ra presents a novel
practical approach for expansion of antigen-specific TCM for adop-
tive immunotherapy.
Differential Expansion and Function of CMVpp65-specific
Memory T-cells
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IN VITRO INDUCTION OF ADENOVIRUS SPECIFIC T-CELLS IN RESPONSE
TO 15-MER PEPTIDES IN UMBILICAL CORD BLOOD
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Human adenovirus (HAdV) infections are a serious life-threat in
hematopoietic stem cell transplantation patients, particularly in chil-
dren. In recent years, umbilical cord blood (UCB) transplants
emerged as an alternative stem cell source. However, the immune
reconstitution is severely hampered in CBT recipients leading to
higher risk of viral infections. Because no effective antiviral medica-
tion exist for severe HAdV infection, replenishing HAdV-specific
immunity through adoptive transfer of HAdV-specific T-cells could
be a promising treatment.
Aim of this study was to induce HAdV-specific T-cells with low
contamination of residual potentially alloreactive T-cells from
UCB. Therefore, cord blood mononuclear cells (CBMCs) were cul-
tured with 5 previously described pan-DR binding 15-mer HAdV
peptides derived from HAdV serotype 5.1 To examine if the mainly
antigen naive UCB T-cells were able to recognize the different
HAdV-peptides, CBMCs of 34 deliveries were cultured with the
HAdV peptides for 5 days without adding supplemental cytokines.
CBMCs of 17 cord blood samples (5 50%) showed a proliferative
response to 43 of the various HAdV-peptides or to the pool of the
peptides, with a stimulation index ranging from 1.7 to 19.1 as deter-
mined by 3H-thymidine proliferation assay. To induce HAdV spe-
cific T-cells, CBMCs derived from 19 deliveries were subsequently
cultured for 7 dayswith theHAdVpeptides or a pool of these peptides
after adding of 40 IU/ml IL2. Compared with medium stimulated
cells HAdV-specific T-cells expressed significantly (p\0.05) more
of the activation markers CD25 and CD69 and harbor a memory
